- Home
- AXSM vs BXP Comparison
AXSM vs BXP Comparison
Compare AXSM & BXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | BXP |
|---|---|---|
| Founded | 2012 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.3B |
| IPO Year | 2015 | 1998 |
Fundamental Metrics
Financial Performance| Metric | AXSM | BXP |
|---|---|---|
| Price | $164.42 | $52.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 19 |
| Target Price | ★ $209.18 | $73.58 |
| AVG Volume (30 Days) | 479.0K | ★ 2.7M |
| Earning Date | 05-18-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.29% |
| EPS Growth | 38.56 | ★ 1833.33 |
| EPS | N/A | ★ 1.74 |
| Revenue | N/A | ★ $3,482,279,000.00 |
| Revenue This Year | $58.34 | $10.94 |
| Revenue Next Year | $54.30 | $3.00 |
| P/E Ratio | ★ N/A | $30.50 |
| Revenue Growth | N/A | ★ 2.19 |
| 52 Week Low | $86.99 | $52.82 |
| 52 Week High | $191.50 | $79.33 |
Technical Indicators
Market Signals| Indicator | AXSM | BXP |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | 27.31 |
| Support Level | $148.14 | N/A |
| Resistance Level | $191.13 | $71.97 |
| Average True Range (ATR) | 5.38 | 1.93 |
| MACD | -1.07 | -0.58 |
| Stochastic Oscillator | 27.82 | 19.97 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About BXP Boston Properties Inc.
BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.